Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6BIWK)

Drug Name
1-naphthylpiperazine Drug Info
Synonyms
1-(1-Naphthyl)piperazine; 1-Naphthylpiperazine; 57536-86-4; 1-(naphthalen-1-yl)piperazine; 1-naphthalen-1-ylpiperazine; 1-Naphthalen-1-yl-piperazine; CHEMBL277120; Piperazine, 1-(1-naphthalenyl)-; Piperazine,1-(1-naphthalenyl)-; 4-(naphth-1-yl)piperazine; Naphthylpiperazine; GTPL3; Lopac-S-003; AC1Q1INU; N-(1-naphthyl)piperazine; 4-(1-naphthyl)piperazine; Biomol-NT_000100; N-(1- naphthyl)piperazine; N-(1-naphthyl)-piperazine; N-(1-naphthyl) piperazine; AC1L1B9K; 4-(1-naphthyl) piperazine; 1-(naphth-1-yl)piperazine; Oprea1_621306; 1-NP
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1342
ChEBI ID
CHEBI:108599
CAS Number
CAS 57536-86-4
TTD Drug ID
DM6BIWK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1B receptor (HTR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
Eletriptan DMW649X Migraine 8A80 Approved [12]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [12]
Frovatriptan DM7RE8P Migraine 8A80 Approved [12]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [12]
Naratriptan DMO50U2 Headache 8A80-8A84 Approved [13]
Prolixin decanoate DMMJ1IS Schizophrenia 6A20 Approved [12]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [14]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [15]
[N-methyl-3H(3)]AZ-10419369 DMSCV02 Mood disorder 6A60-6E23 Phase 1 [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [17]
Eletriptan DMW649X Migraine 8A80 Approved [12]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [12]
Frovatriptan DM7RE8P Migraine 8A80 Approved [12]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [18]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [19]
Almogran DM7I64Z Migraine 8A80 Approved [20]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [21]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [22]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [23]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [24]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [25]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [26]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [25]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [27]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [28]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [24]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [29]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [31]
Triflupromazine DMKFQJP Nausea MD90 Approved [32]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [33]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [34]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [35]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [36]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [37]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [37]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [37]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [31]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [38]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [39]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [40]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [41]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [42]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [43]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [44]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [45]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1F receptor (HTR1F)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [6]
Lasmiditan DMXLVDT Migraine 8A80 Approved [47]
LY-334370 DM43O9N Migraine 8A80 Phase 2 [48]
5-CT DM260KD Discovery agent N.A. Investigative [6]
TFMPP DMAC8TP Discovery agent N.A. Investigative [49]
BRL-15572 DMM61Y2 Discovery agent N.A. Investigative [50]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [49]
alpha-methyl-5-HT DMCAYXF Discovery agent N.A. Investigative [49]
WAY-466 DMMOH51 Discovery agent N.A. Investigative [51]
[125I]LSD DMP69QG Discovery agent N.A. Investigative [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [12]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [53]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [54]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [55]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [40]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [56]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [57]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [58]
Treximet DMU54QB Migraine 8A80 Approved [59]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [60]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [22]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [61]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [62]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [63]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [64]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [64]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [65]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [65]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [66]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1E receptor (HTR1E)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [5]
5-CT DM260KD Discovery agent N.A. Investigative [5]
TFMPP DMAC8TP Discovery agent N.A. Investigative [5]
BRL-15572 DMM61Y2 Discovery agent N.A. Investigative [50]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [49]
alpha-methyl-5-HT DMCAYXF Discovery agent N.A. Investigative [5]
m-chlorophenylpiperazine DMM1J2D Discovery agent N.A. Investigative [5]
EDMT DMS3AXK Discovery agent N.A. Investigative [68]
9-OH-risperidone DMGORXQ Discovery agent N.A. Investigative [69]
[3H]5-HT DMYJXV7 Discovery agent N.A. Investigative [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [71]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [72]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [73]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [74]
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [75]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [76]
Ibandronate DM0QZBN Hypercalcaemia 5B91.0 Approved [77]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [78]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [79]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [80]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Agonist [2]
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Agonist [3]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [4]
5-HT 1E receptor (HTR1E) TTCPG9S 5HT1E_HUMAN Antagonist [5]
5-HT 1F receptor (HTR1F) TT0MI3F 5HT1F_HUMAN Antagonist [6]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [7]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Antagonist [8]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Agonist [9]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Agonist [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Gene/Protein Processing [11]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3).
2 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8.
3 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
4 Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.
5 Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
6 Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
7 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
8 Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
9 Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7.
10 Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422-6.
11 Cytotoxic effect of the serotonergic drug 1-(1-Naphthyl)piperazine against melanoma cells. Toxicol In Vitro. 2018 Mar;47:72-78.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
14 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
15 Company report (NeurAxon)
16 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
17 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
18 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
19 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
20 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
21 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
22 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
23 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
24 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
25 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
26 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
27 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
28 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
29 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
30 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
31 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
32 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
33 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
34 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
35 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
36 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
37 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
38 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
39 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
40 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
41 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
42 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
43 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
44 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
45 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
46 Clinical pipeline report, company report or official report of Lundbeck.
47 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
48 Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4.
49 Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
50 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
51 Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
52 Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus. J Biol Chem. 1992 Oct 5;267(28):19761-4.
53 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
54 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
55 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
56 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
57 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
58 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
59 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
61 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
62 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
63 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
64 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
65 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
66 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
67 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
68 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
69 Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
70 Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5517-21.
71 Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
72 Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
73 Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
74 COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
75 Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
76 Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
77 Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
78 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
79 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
80 A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.